![]() ![]() ![]() Everything else can be put in a bucket labeled "alternative investments."įor good measure, I'll typically list hedge funds, crypto funds, venture capital, private equity, commodities, real estate, private debt, and art and collectibles as examples of alternative investments or “alts” for short. Sure, it's a pretty disparate list of products, but it's what they have in common that's fueling the appetite for alternatives.Īn attribute all alts share is they are less correlated-in some cases completely uncorrelated-to the broader market. Over the years, I've boiled that explanation down to simply this: stocks, bonds, and cash are traditional investments. It's this capital that needs help to be deployed, unfettered by archaic regulation and other barriers to entry.įor the time being, "alternative investments" remains a term I have to explain pretty often in my interactions with people outside of the finance industry. This story originally appeared on Fintel.However, the projected total value of the alternative assets under management is just a tenth of the $170 trillion in assets collectively held by high-net-worth individuals globally. Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial e.Randomized 1:1:1:1 to 1 of 4 treatment arms, stratified by sex and baseline BMI, with standard lifestyle interventions.Phase 2, 48-week trial of pemvidutide in approx 320 subjects with overweight or obesity.Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial.Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D.Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase.Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™) an intranasal immune modulating therapeutic for COVID-19 (T-COVID™) and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). (This description is provided by the company.)Īltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The firm decreased its portfolio allocation in ALT by 57.41% over the last quarter. In it's prior filing, the firm reported owning 1,159K shares, representing an increase of 43.29%. The firm decreased its portfolio allocation in ALT by 73.21% over the last quarter.Ĭitadel Advisors holds 2,044K shares representing 4.15% ownership of the company. In it's prior filing, the firm reported owning 2,700K shares, representing an increase of 1.80%. Tang Capital Management holds 2,750K shares representing 5.58% ownership of the company. ![]() The firm decreased its portfolio allocation in ALT by 36.29% over the last quarter. In it's prior filing, the firm reported owning 3,266K shares, representing an increase of 0.06%. Nuveen Asset Management holds 3,268K shares representing 6.63% ownership of the company. The firm increased its portfolio allocation in ALT by 74.08% over the last quarter. In it's prior filing, the firm reported owning 751K shares, representing an increase of 78.54%. Laurion Capital Management holds 3,501K shares representing 7.10% ownership of the company. The firm decreased its portfolio allocation in ALT by 73.46% over the last quarter. In it's prior filing, the firm reported owning 5,785K shares, representing a decrease of 20.74%. XBI - SPDR(R) S&P(R) Biotech ETF holds 4,791K shares representing 9.72% ownership of the company. The put/call ratio of ALT is 0.14, indicating a bullish outlook. Total shares owned by institutions decreased in the last three months by 6.16% to 50,022K shares. Average portfolio weight of all funds dedicated to ALT is 0.08%, a decrease of 63.85%. This is an increase of 4 owner(s) or 1.91% in the last quarter. There are 213 funds or institutions reporting positions in Altimmune. The projected annual non-GAAP EPS is -2.18. The projected annual revenue for Altimmune is 0MM. See our leaderboard of companies with the largest price target upside. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |